|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300075486 |
|
最近更新日期: Date of Last Refreshed on: |
2023-09-06 15:23:00 |
|
注册时间: Date of Registration: |
2023-09-06 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于中医体质的壮医药线点灸对MCI患者的干预研究 |
|
Public title: |
Study of Zhuang medicated thread moxibustion for patients with Mild Cognitive Impairment based on Traditional Chinese Medicine constitution |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于中医体质的壮医药线点灸对MCI患者的干预研究 |
|
Scientific title: |
Study of Zhuang medicated thread moxibustion for patients with Mild Cognitive Impairment based on Traditional Chinese Medicine constitution |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄新格 |
研究负责人: |
赵利华 |
|
Applicant: |
Huang Xinge |
Study leader: |
Zhao Li hua |
|
申请注册联系人电话: Applicant telephone: |
+86 138 7812 9010 |
研究负责人电话:
Study leader's |
+86 130 0691 3108 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
511937296@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zhaolh@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广西南宁市西乡塘区明秀东路181号 |
研究负责人通讯地址: |
广西南宁市西乡塘区明秀东路181号 |
|
Applicant address: |
181 Mingxiu dong Road, Nanning, Guangxi, China |
Study leader's address: |
181 Mingxiu dong Road, Nanning, Guangxi, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广西中医药大学第一附属医院 |
||
|
Applicant's institution: |
First Affiliated Hospital, Guangxi University of Chinese Medicine |
||
|
研究负责人所在单位: |
广西中医药大学第一附属医院 |
||
|
Affiliation of the Leader: |
First Affiliated Hospital, Guangxi University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-059-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广西中医药大学第一附属医院伦理委员会 |
||
|
Name of the ethic committee: |
IEC for the First Affiliated Hospital of Guangxi University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-08-31 00:00:00 | ||
|
伦理委员会联系人: |
黎老师 |
||
|
Contact Name of the ethic committee: |
Teacher Li |
||
|
伦理委员会联系地址: |
广西中医药大学第一附属医院 |
||
|
Contact Address of the ethic committee: |
First Affiliated Hospital, Guangxi University of Chinese Medicine |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 771 562 3535 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广西中医药大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
First Affiliated Hospital, Guangxi University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广西南宁市东葛路89-9号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
89-9 Dongge Road, Nanning, Guangxi, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广西中医药适宜技术开发与推广项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Project for the Development and Promotion of Appropriate Technologies for Traditional Chinese Medicine in Guangxi |
||||||||||||||||||||||
|
研究疾病: |
轻度认知障碍 |
||||||||||||||||||||||
|
Target disease: |
Mild Cognitive Impairment based on Traditional Chinese Medicine constitution |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)构建壮医药线点灸防治MCI易患体质调养关键技术方案,为早期诊断及治疗MCI及防治AD提供调质防病的壮医药线点灸规范的诊疗方案规范。 (2)在3家以上的中医院及社区医院推广应用本项目技术,提高本地区壮医技术防治MCI的医疗水平。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) Develop a comprehensive technical program for Zhuang medicated thread moxibustion to effectively prevent and treat mild cognitive impairment (MCI). Establish standardized treatment protocols for early diagnosis and treatment of MCI, as well as for the prevention and treatment of Alzheimer's disease (AD). (2) Promote the application of the project technology in more than three Chinese medicine hospitals and community hospitals to improve the medical level of Zhuang medicine technology for the prevention and treatment of MCI in the region. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①与MCI的诊断标准相符合的患者;②存在记忆障碍( 自诉并有知情者证实),MMSE评分在22-27之间;③符合《中医体质分类与判定》标准的阳虚质、瘀血质或痰湿质;④年龄55-75岁;⑤其它认知功能相对正常或轻度损害;⑥日常生活能力和社会职业未受影响;⑦其记忆力的损害尚未达到痴呆的诊断标准;⑧排除其他任何可以引起脑功能障碍的系统疾病;⑨受试者或者监护人签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
①Patients fulfilling diagnostic criteria for Mild Cognitive Impairment; ②Memory impairment (self-reported and confirmed by an informed person) with an MMSE score between 22 and 27;③ Yang deficiency, blood stasis, or phlegm dampness meeting the criteria of the Classification and Determination of Physical Qualities in Traditional Chinese Medicine; ④Age between 55-75 years; ⑤ Relatively normal or mildly impaired cognitive functions other than memory; ⑥Daily living ability and social occupation remain unaffected; ⑦Memory impairment did not meet the diagnostic criteria for dementia; ⑧Exclusion of any systemic diseases potentially causing brain dysfunction; (9) Informed consent signed by the subject or guardian. |
||||||||||||||||||||||
|
排除标准: |
①有晚期、严重或不稳定的其他疾病,如肝脏、肾脏等严重原发性疾病;②严重的听力、视力障碍者,不能配合评估;③正处于活动性癫痫患者;④既往有精神病病史;⑤有痴呆、脑梗死或任何可以导致脑功能紊乱的躯体和精神疾患;⑥纳入前应用过其他可能引起认知功能变化或者心脑肾等重要器官衰竭药物的患者;⑦年龄在55岁以下或75岁以上的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
①Those with advanced, severe, or unstable comorbidities, such as liver or kidney disease, or other serious underlying medical conditions. ②Individuals with profound hearing or visual impairment who are unable to cooperate with the assessment. ③Those with active epilepsy. ④ Individuals with a history of psychiatric disorders. ⑤Those with dementia, cerebral infarction, or any neurological or psychiatric disorder that may impact cognitive function.⑥Individuals who have been previously prescribed medications that may affect cognitive function or vital organs, such as the heart, brain, or kidneys. ⑦Individuals under 55 or over 75 years old. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-01-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-09-01 00:00:00 至 To 2024-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用随机对照法:由计算机产生的中心随机方案,由专人负责保管,除设计者及中心随机负责人之外,其他研究人员均不得知晓随机方案。临床医师根据患者的入组序号向中心随机员索取随机号及该患者所纳入的组别编号,然后按照事先制定的各组治疗方案进行临床研究。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study utilized a randomized controlled design,and it adopted a computer-generated center randomized program that was kept by the designer and the random director of the center.The clinician requested the randomization number and the included group number of the patient according to the enrollment number, and then conducts the clinical study according to the prior treatment plan of each group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究采用患者盲以及第三者评价盲法。 |
|
Blinding: |
The patient blindness and the third party evaluation blindness were used in this study. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成6个月后,Resman |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the completion of the trial, Resman |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据保存在临床试验数据管理公共平台,专家指导自行管理,包括原始数据,病例报告表,用excel数据表。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data are stored in the Clinical trial data management public platform, with expert guidance for self-management, including raw data, case report form, and excel data sheet. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |